Bristol-Myers Squibb Company (BMY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $129.66B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bristol-Myers Squibb Company (BMY) Earnings: Report Dates and Results
Bristol-Myers Squibb Company (BMY) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Bristol-Myers Squibb Company reported EPS of $1.35, above the $1.21 estimate. It beat the EPS estimate in each of the last 10 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
BMY has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.0% above the $1.26 reported for the quarter ended Dec 31, 2025.
BMY Earnings Call
The latest BMY earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, BMY beat 35 and missed 5. Revenue for the quarter ended Sep 30, 2026 was $13.07B, up 7.0% from $12.22B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.35 | $1.21 | $0.98 - $1.75 | +11.57% | Beat | -17.2% | 23 | 1 up, 8 down | Oct 29, 2026 | $13.07B |
| Jun 30, 2026 | $2.04 | $1.59 | $1.48 - $1.68 | +28.30% | Beat | +39.7% | 23 | 0 up, 3 down | Jul 30, 2026 | $12.97B |
| Mar 31, 2026 | $1.58 | $1.42 | $1.23 - $1.53 | +11.27% | Beat | -12.2% | 24 | 5 up, 11 down | Apr 30, 2026 | $11.49B |
| Dec 31, 2025 | $1.26 | $1.20 | $0.88 - $1.66 | +5.00% | Beat | -24.6% | 20 | 0 up, 14 down | Feb 5, 2026 | $12.50B |
| Sep 30, 2025 | $1.63 | $1.52 | $1.35 - $1.74 | +7.24% | Beat | -9.4% | 21 | 1 up, 13 down | Oct 30, 2025 | $12.22B |
| Jun 30, 2025 | $1.46 | $1.10 | $0.96 - $1.67 | +32.73% | Beat | -29.5% | 21 | 1 up, 14 down | Jul 31, 2025 | $12.27B |
| Mar 31, 2025 | $1.80 | $1.50 | $1.42 - $1.63 | +20.00% | Beat | N/A | 20 | 2 up, 6 down | Apr 24, 2025 | $11.20B |
| Dec 31, 2024 | $1.67 | $1.47 | $1.41 - $1.60 | +13.61% | Beat | +5.0% | 20 | 6 up, 6 down | Feb 6, 2025 | $12.34B |
| Sep 30, 2024 | $1.80 | $1.50 | $1.38 - $1.62 | +20.00% | Beat | -10.0% | 18 | 1 up, 1 down | Oct 31, 2024 | $11.89B |
| Jun 30, 2024 | $2.07 | $1.63 | $1.52 - $1.76 | +26.99% | Beat | +18.3% | 17 | 6 up, 2 down | Jul 26, 2024 | $12.20B |
| Mar 31, 2024 | -$4.40 | -$4.14 | -$4.78 - -$3.27 | -6.28% | Miss | -314.6% | 17 | 0 up, 4 down | Apr 25, 2024 | $11.87B |
| Dec 31, 2023 | $1.59 | $1.43 | $1.38 - $1.76 | +11.19% | Beat | -12.6% | 17 | 0 up, 4 down | Feb 2, 2024 | $11.48B |
| Sep 30, 2023 | $2.00 | $1.77 | $1.67 - $1.86 | +12.99% | Beat | +0.5% | 18 | 2 up, 1 down | Oct 26, 2023 | $10.97B |
| Jun 30, 2023 | $1.75 | $1.99 | $1.86 - $2.04 | -12.06% | Miss | -9.3% | 20 | 4 up, 3 down | Jul 27, 2023 | $11.23B |
| Mar 31, 2023 | $2.05 | $1.97 | $1.87 - $2.07 | +4.06% | Beat | +4.6% | 19 | 3 up, 3 down | Apr 27, 2023 | $11.34B |
| Dec 31, 2022 | $1.82 | $1.73 | $1.61 - $1.83 | +5.20% | Beat | -0.5% | 18 | 6 up, 1 down | Feb 2, 2023 | $11.41B |
| Sep 30, 2022 | $1.99 | $1.83 | $1.74 - $1.91 | +8.74% | Beat | -0.5% | 16 | 4 up, 0 down | Oct 25, 2022 | $11.22B |
| Jun 30, 2022 | $1.93 | $1.80 | $1.68 - $1.93 | +7.22% | Beat | 0.0% | 16 | 1 up, 3 down | Jul 27, 2022 | $11.89B |
| Mar 31, 2022 | $1.96 | $1.90 | $1.74 - $1.97 | +3.16% | Beat | +12.6% | 16 | 3 up, 4 down | Apr 29, 2022 | $11.65B |
| Dec 31, 2021 | $1.83 | $1.80 | $1.73 - $1.85 | +1.67% | Beat | +25.3% | 17 | 2 up, 3 down | Feb 4, 2022 | $11.98B |
| Sep 30, 2021 | $2.00 | $1.92 | $1.86 - $2.02 | +4.17% | Beat | +22.7% | 12 | N/A | Oct 27, 2021 | $11.62B |
| Jun 30, 2021 | $1.93 | $1.90 | $1.81 - $2.00 | +1.58% | Beat | +18.4% | 13 | N/A | Jul 28, 2021 | $11.70B |
| Mar 31, 2021 | $1.74 | $1.81 | $1.70 - $1.96 | -3.87% | Miss | +1.2% | 13 | N/A | Apr 29, 2021 | $11.07B |
| Dec 31, 2020 | $1.46 | $1.42 | $1.35 - $1.60 | +2.82% | Beat | +19.7% | 14 | N/A | Feb 4, 2021 | $11.07B |
| Sep 30, 2020 | $1.63 | $1.49 | $1.43 - $1.57 | +9.40% | Beat | +39.3% | 14 | N/A | Nov 5, 2020 | $10.54B |
| Jun 30, 2020 | $1.63 | $1.48 | $1.38 - $1.62 | +10.14% | Beat | +38.1% | 12 | N/A | Aug 6, 2020 | $10.13B |
| Mar 31, 2020 | $1.72 | $1.45 | $1.38 - $1.57 | +18.62% | Beat | +56.4% | 11 | N/A | May 7, 2020 | $10.78B |
| Dec 31, 2019 | $1.22 | $1.16 | N/A | +5.17% | Beat | +29.8% | 4 | N/A | Feb 6, 2020 | $7.95B |
| Sep 30, 2019 | $1.17 | $1.07 | $1.03 - $1.14 | +9.35% | Beat | +7.3% | 10 | N/A | Oct 31, 2019 | $6.01B |
| Jun 30, 2019 | $1.18 | $1.06 | $1.03 - $1.09 | +11.32% | Beat | +16.8% | 10 | N/A | Jul 25, 2019 | $6.27B |
| Mar 31, 2019 | $1.10 | $1.08 | $1.05 - $1.16 | +1.85% | Beat | +17.0% | 11 | N/A | Apr 25, 2019 | $5.92B |
| Dec 31, 2018 | $0.94 | $0.85 | $0.80 - $0.95 | +10.59% | Beat | +38.2% | 11 | N/A | Jan 24, 2019 | $5.97B |
| Sep 30, 2018 | $1.09 | $0.91 | $0.86 - $0.96 | +19.78% | Beat | +45.3% | 14 | N/A | Oct 25, 2018 | $5.69B |
| Jun 30, 2018 | $1.01 | $0.87 | $0.84 - $0.91 | +16.09% | Beat | +36.5% | 14 | N/A | Jul 26, 2018 | $5.70B |
| Mar 31, 2018 | $0.94 | $0.85 | $0.79 - $0.92 | +10.59% | Beat | +11.9% | 17 | N/A | Apr 26, 2018 | $5.19B |
| Dec 31, 2017 | $0.68 | $0.67 | $0.63 - $0.72 | +1.49% | Beat | +7.9% | 19 | N/A | Feb 5, 2018 | $5.45B |
| Sep 30, 2017 | $0.75 | $0.77 | $0.72 - $0.81 | -2.60% | Miss | -2.6% | 19 | N/A | Oct 26, 2017 | $5.25B |
| Jun 30, 2017 | $0.74 | $0.73 | $0.70 - $0.78 | +1.37% | Beat | +7.2% | 18 | N/A | Jul 27, 2017 | $5.14B |
| Mar 31, 2017 | $0.84 | $0.74 | N/A | +13.51% | Beat | +13.5% | N/A | N/A | Apr 27, 2017 | $4.93B |
| Dec 31, 2016 | $0.63 | $0.66 | N/A | -4.55% | Miss | +65.8% | N/A | N/A | Jan 26, 2017 | $5.24B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $6.15, up 439.5% from the year before. It was $2.83 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $6.15 | +439.5% |
| Dec 31, 2024 | $1.14 | -84.6% |
| Dec 31, 2023 | $7.39 | -4.0% |
| Dec 31, 2022 | $7.70 | +2.7% |
| Dec 31, 2021 | $7.50 | +16.5% |
| Dec 31, 2020 | $6.44 | +37.9% |
| Dec 31, 2019 | $4.67 | +17.3% |
| Dec 31, 2018 | $3.98 | +32.2% |
| Dec 31, 2017 | $3.01 | +6.4% |
| Dec 31, 2016 | $2.83 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,200 words across 20 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,173 | 20 | |
| 2026Q2 | Jun 30, 2026 | 7,473 | 19 | |
| 2026Q1 | Mar 31, 2026 | 7,771 | 17 | |
| 2025Q4 | Dec 31, 2025 | 9,610 | 19 | |
| 2025Q3 | Sep 30, 2025 | 9,031 | 20 | |
| 2025Q2 | Jun 30, 2025 | 9,578 | 19 | |
| 2025Q1 | Mar 31, 2025 | 9,457 | 25 | |
| 2024Q4 | Dec 31, 2024 | 12,557 | 26 |
2026Q3 Earnings Call
Opening remarks
Charles E. Triano Senior Vice President and Head of Investor Relations Thank you, and good morning, everyone. We appreciate you joining our third quarter 2026 earnings call. With me this morning for prepared remarks are Christopher S. Boerner, our Board Chair and Chief Executive Officer, and David V. Elkins, our Chief Financial Officer. Also participating in today's call are Adam Lenkowsky, our Chief Commercialization Officer, and Cristian Massacesi, our Chief Medical Officer and Head of Global Drug Development. Earlier this morning, we posted our quarterly slide presentation to bms.com, which you can use to follow along with Christopher and David's remarks. Before we get started, I will remind everybody that during this call, we will make statements about the company's future plans and prospects that constitute forward-looking statements. Actual results may differ materially from those indicated by those forward-looking statements as a result of various important factors, including those discussed in the company's SEC filings. These forward-looking statements represent our estimates as of today and should not be relied upon as representing our estimates as of any future date. We specifically disclaim any obligation to update forward-looking statements, even if our estimates change. We will also focus our comments on our non-GAAP financial measures, which are adjusted to exclude certain specified items. Reconciliations of certain non-GAAP financial measures to the most comparable GAAP measure are available at bms.com. Finally, unless otherwise stated, all comparisons are made with the same period in 2025, and sales growth rates will be discussed on an underlying basis, which excludes the impact of foreign exchange. All references to our P&L are on a non-GAAP basis. With that, I will hand it over to Christopher.
Christopher S. Boerner Board Chair and Chief Executive Officer Thanks, Chuck. Good morning, everyone, and thank you for joining our Q3 2026 earnings call. We reported another quarter of double-digit growth in our growth portfolio and progressed our plans to de-risk the pipeline to position the company for long-term success. We have seen several positive registrational readouts and regulatory approvals over the past few months, and we expect more to come, bringing the next wave of launches into sharper focus. We are executing well commercially, our differentiated pipeline is advancing nicely, and we continue to operate with discipline, which gives us strategic flexibility to invest for sustainable growth. Based on the strength of our results, we are raising our full-year guidance. David will provide additional details on this shortly. Let me start with our Q3 performance on Slide 4. Our growth portfolio continues to deliver solid results, with sales increasing 12%, driven by a broad set of differentiated products. We generated strong performance in key brands, including Reblozyl, Breyanzi, Opdualag, Qvantig, and Camzyos. We also continue to expand the reach of our medicines.
Frequently Asked Questions About BMY
When is Bristol-Myers Squibb Company's next earnings date?
Bristol-Myers Squibb Company's next earnings report is expected for Feb 3, 2027.
Did BMY beat earnings estimates last quarter?
Yes. Bristol-Myers Squibb Company reported EPS of $1.35 for the quarter ended Sep 30, 2026, above the $1.21 estimate, a 11.57% surprise.
What EPS do analysts expect from BMY next quarter?
The consensus EPS estimate for Bristol-Myers Squibb Company for the quarter ending Dec 31, 2026 is $1.50 from 25 analysts, with estimates from $1.29 to $1.69.
How often does BMY beat earnings estimates?
Bristol-Myers Squibb Company beat the EPS estimate in each of the last 10 quarters, with an average surprise of +17.67%.
BMY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts